This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the official electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal Register documents. Each document posted on the site includes a link to the corresponding official PDF file on govinfo.gov. This prototype edition of the daily Federal Register on FederalRegister.gov will remain an unofficial informational resource until the Administrative Committee of the Federal Register (ACFR) issues a regulation granting it official legal status. For complete information about, and access to, our official publications and services, go to About the Federal Register on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable regulatory information on FederalRegister.gov with the objective of establishing the XML-based Federal Register as an ACFR-sanctioned publication in the future. While every effort has been made to ensure that the material on FederalRegister.gov is accurately displayed, consistent with the official SGML-based PDF version on govinfo.gov, those relying on it for legal research should verify their results against an official edition of the Federal Register. Until the ACFR grants it official status, the XML rendition of the daily Federal Register on FederalRegister.gov does not provide legal notice to the public or judicial notice to the courts.
Food and Drug Administration, HHS.
Withdrawal of proposed rules.
The Food and Drug Administration (FDA) is announcing the withdrawal of certain advance notice of proposed rulemakings (ANPRMs), proposed rules, and other proposed actions that published in the Federal Register more than 5 years ago. These proposals are no longer considered viable candidates for final action at this time. FDA is taking this action to reduce its regulatory backlog and focus its resources on current public health issues. The FDA's actions are part of an overall regulatory reform strategy initiated by Health and Human Services (HHS) Secretary Tommy G. Thompson.
The proposed rules are withdrawn as of November 26, 2004.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Lisa M. Helmanis, Regulations Policy and Management Staff (HF-26), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-3480.End Further Info End Preamble Start Supplemental Information
On June 8, 2001, Secretary Thompson announced his regulatory reform initiative designed to reduce regulatory burdens in health care and respond faster to the concerns of health care providers, State and local governments, and individual Americans who are affected by HHS rules. In December 2001, the Secretary announced the membership of his Regulatory Reform Committee designed to carry out his initiative. In November 2002, the Committee released its final report with over 255 specific recommendations for simplifying, streamlining, and generally reducing the regulatory burden while Start Printed Page 68832continuing to require accountability by those doing business with HHS and its agencies. Over 25 of the recommendations have been adopted, and the Secretary charged the Office of the Assistant Secretary for Planning and Evaluation to continue the efforts of the Regulatory Reform Committee. FDA's continuing efforts to finalize or withdraw regulations that have been proposed but not finalized are part of this overall initiative.
In 1990, FDA began this process of conducting periodic, comprehensive reviews of its regulations process that included reviewing the backlog of ANPRMs, notices of proposed rulemaking, and other notices for which no final action or withdrawal notice had been issued. In the Federal Register of December 30, 1991 (56 FR 67440), FDA issued its first notice withdrawing 89 proposed rules that had published before December 31, 1985, but had never been finalized. Then again, in the Federal Register of January 20, 1994 (59 FR 3042), the agency withdrew an additional nine outstanding proposed rules.
Once again, on April 22, 2003, FDA published a notice in the Federal Register (68 FR 19766) announcing its intent to withdraw 84 proposed rules and other proposed actions that had published in the Federal Register more than 5 years ago, but that had never been finalized. Included in this list were 19 proposed rules that were originally proposed for withdrawal in 1991, but at that time the agency decided to defer its decision to withdraw or finalize them until a later date.
The agency undertook this most recent review because it believes that the backlog of pending proposals dilutes its ability to concentrate on higher priority regulations that are mandated by statute or are necessary to address current public health issues. Because of the agency's limited resources and changing priorities, FDA has been unable to: (1) Consider, in a timely manner, the issues raised by the comments on these proposals and (2) complete the action on them. Additionally, because many of the proposals have become outdated in the time that has elapsed since their publication, the agency would need to obtain further comment on them before proceeding to final action. FDA has determined that the proposals identified in this document are lower in priority than those on the Unified Agenda and the Regulatory Plan. It is unlikely that the agency will have sufficient resources in the foreseeable future to further consider or prioritize these proposed rules. Although not required to do so by the Administrative Procedure Act or by regulations of the Office of the Federal Register, the agency believes the public interest is best served by withdrawing the proposals identified in this document. In some instances, the agency has already completed action on alternatives (e.g., the issuance of guidance or inclusion of provisions in related regulations) that have obviated the need to complete the proposed action. In addition, the agency notes that upon reviewing the comments and other records related to the rulemaking, the agency found that “Amend Animal Care Regulations” (Docket No. 89P-0320 (July 3, 1990, 55 FR 27476)) was the subject of a petition, and the agency assigned another docket number to that action. This action was finalized on July 15, 1991 (56 FR 32087), and therefore it is not necessary to be included in this withdrawal notice.
The withdrawal of the proposals identified in this document does not preclude the agency from reinstituting proceedings to issue rules concerning the issues addressed in the proposals listed in table 1 of this document. Should FDA decide to undertake such a rulemaking sometime in the future, it will repropose the actions and provide new opportunities for comment.
The agency notes that withdrawal of a proposal is not intended to affect whatever utility the preamble statements may currently have as indications of FDA's position on a matter at the time the proposal was published, and in some cases the preambles of these proposals may still reflect the current position of FDA on the matter addressed. Anyone unsure whether a statement in one of the preambles reflects the agency's current thinking should contact FDA.
II. Summary of and Responses to Comments
FDA received a total of 37 letters, each containing 1 or more comments, in response to its notice of intent to withdraw certain proposed rules. The following is a discussion of the comments and the agency's response to those comments.
A. General Comments
(Comment 1) One comment provided recommendations on FDA's overall withdrawal process and the way information in the notice of intent was presented to the public. The comment requested that the agency identify how it intended to handle each individual item included in the notice of intent including reasons for withdrawal and future actions. The comment also requested that the agency identify which preambles will continue to reflect the agency's current thinking even after the proposed rule has been withdrawn. Finally, the comment thought that FDA should have made all the proposed actions listed in the notice of intent available on FDA's Web site for easy access to all interested parties.
(Response) The agency disagrees with these comments. The agency's decisions on the items proposed to be withdrawn were based on the general factors described in the notice of intent and whether the proposals fell within the listed factors. When the agency published the notice of intent, it did not have definite future plans for any of the items listed. The reason the agency stated that it may take future action was to emphasize that the withdrawals were based on resources and priorities. A withdrawal does not prevent the agency from taking action in the future on its own initiative or as a result of being prompted by the public. Also, a withdrawal of a proposed rule neither affirms nor rejects the views contained in the preamble. If someone wants a clarification of any agency policy or position, they should contact FDA.
While not providing copies on its Web site, the agency provided the title, docket number, and Federal Register publication date and cite. The agency believes that, in most cases, this information was sufficient to allow readers to find the documents whether online or in a library. Also, the agency provided the name, address, and phone number of an FDA contact who was prepared to provide copies of each proposal, if requested. Therefore, none of these issues raised by this comment would have affected the ability of the public to comment on the items listed in the notice of intent.
(Comment 2) One comment opposed the withdrawal of all the proposed generally recognized as safe (GRAS) actions listed in the notice of intent unless FDA could provide assurance that the agency would continue to permit the use of these food ingredients as detailed in the preamble statements.
(Response) This withdrawal does not affect the regulatory status of the ingredients listed in these documents. Furthermore, the comment did not raise any issues not considered by FDA before publication of the notice of intent to withdraw. Therefore, FDA is withdrawing all the GRAS proposed rules listed in the notice of intent.
(Comment 3) One comment recommended that the agency withdraw an ANPRM on hearing aids (58 FR 59695, November 10, 1993) that was not included in the notice of intent.Start Printed Page 68833
(Response) While the agency agrees that this ANPRM is a good candidate for withdrawal, because it was not included in the original notice of intent, we will withdraw or take other action with respect to this proposal separately, in a future Federal Register notice.
B. Specific Comments
The agency received specific comments on 17 of the documents listed in the notice of intent. These comments generally supported FDA's attempt at streamlining the regulations process, and in some cases, supported the agency's decision to withdraw a certain proposed rule. However, several of these comments opposed the agency's decision to withdraw a proposal. The specific comments received, and the agency's responses are as follows:
1. Cosmetic Products Containing Certain Hormone Ingredients—Docket No. 91N-0245, September 9, 1993, 58 FR 47611
FDA received 9 comments opposing the withdrawal of this proposed rule.
(Comment 4) These comments argued that the withdrawal of this proposed rule would call into question the findings presented in the proposed rule and possibly change the marketing status of cosmetic products containing hormone ingredients.
(Response) With regard to the first concern, as stated previously in this document, this withdrawal neither affirms nor rejects statements contained in the preamble. With regard to the second concern, the proposed rule was never finalized, and therefore withdrawal of the proposed rule does not affect the marketing status of these products. The agency intends to issue a new proposed rule regarding these products in the future.
2. Caffeine in Nonalcoholic Carbonated Beverages—Docket No. 82N-0318, May 20, 1987, 52 FR 18923
3. Shellac and Shellac Wax; Proposed Affirmation of GRAS Status With Specific Limitations as Direct Human Food Ingredients—Docket No. 89N-0106, July 26, 1989, 54 FR 31055
4. Unmodified Food Starches and Acid-Modified Starches; Proposed Affirmation of GRAS Status as Direct and Indirect Food Ingredient—Docket No. 84N-0341, April 1, 1985, 50 FR 12821
5. Caffeine; Deletion of GRAS Status; Proposed Declaration That No Prior Sanction Exists and Use on an Interim Basis Pending Additional Study—Docket No. 80N-0418, October 21, 1980, 45 FR 69817
6. Protein Hydrolysates and Enzymatically Hydrolyzed Animal (Milk Casein) Protein; Proposed GRAS Status—Docket No. 82N-0006, December 8, 1983, 48 FR 54990
7. Cellulose Derivatives; Affirmation of GRAS Status—Docket No. 78N-0144, February 23, 1979, 44 FR 10751
(Comment 5) FDA received five comments on these six GRAS proposed rules. The majority of the comments opposed the withdrawal of these proposals.
(Response) None of the comments raised issues not considered by the agency before publication of the notice of intent to withdraw. Therefore, FDA is withdrawing all the GRAS proposed rules listed in the notice of intent. However, this withdrawal does not affect the regulatory status of the ingredients listed in these documents.
8. Reclassification of Electroconvulsive Therapy—Docket No. 82P-0316, September 5, 1990, 55 FR 36578
(Comment 6) FDA received one comment supporting the withdrawal of this proposed rule. However, the comment was concerned that the information contained in this docket (i.e., reports of adverse reactions) would be disregarded when the proposed rule was withdrawn.
(Response) The agency is withdrawing this proposed rule, and in the future, intends to start a new proceeding on this matter. The agency will retain the data and information contained in this docket and consider it at that time.
9. Food Labeling; Declaration of Ingredients; Common or Usual Name Declaration for Protein Hydrolysates and Vegetable Broth in Canned Tuna; “and/or” Labeling for Soft Drinks—Docket No. 90N-361M, January 6, 1993, 58 FR 2950
(Comment 7) FDA received 15 comments supporting and one comment opposing the withdrawal of this proposed rule. The comment opposing the withdrawal of this proposed rule stated that the proposed rule memorialized the development of the agency's policy on “and/or” labeling for sweeteners in soft drinks and is the sole source of reference on these matters. The comment expressed concern that withdrawal may call into question current and future labeling practices of the soft drink industry regarding sweeteners in soft drinks.
(Response) The agency disagrees with this comment's implication that the proposed rule announced a final FDA policy decision on “and/or” labeling for sweeteners in soft drinks. By definition, a proposed rule only states the agency's tentative conclusions; with limited exceptions not applicable here, final decisions in the rulemaking context must be issued in a final rule after public notice and opportunity for comment (see 5 U.S.C. 553(b) to (c)). Further, the agency stated in the preamble to the proposed rule (58 FR 2950 at 2953) that its final decision on whether to revise its regulations to permit “and/or” labeling for sweeteners in soft drinks would be based largely on whether comments in response to the proposed rule included data demonstrating that it is impracticable to produce the limited number of versions of a label that would be necessary if “and/or” labeling were not permitted. The agency received no such data and therefore did not have sufficient basis to proceed to a final rule allowing “and/or” labeling for soft drinks. Accordingly, this comment does not persuade the agency to reconsider the withdrawal of this proposed rule.
Comments supporting the withdrawal of this proposal asked that the agency initiate enforcement action against soft drink manufacturers that use “and/or” labeling. The agency acknowledges that it has not pursued any enforcement action against soft drink manufacturers who are using “and/or” labeling because of the pending rulemaking. The agency is considering its position on the use of “and/or” labeling.
10. Yogurt Products; Frozen Yogurt, Frozen Lowfat Yogurt; and Frozen Nonfat Yogurt; Petitions to Establish Standards of Identity and to Amend Existing Standards—Docket Nos. 89P-0208 and 89P-0444, May 31, 1991, 56 FR 24760
(Comment 8) The agency received one comment supporting the withdrawal of this proposed rule. The comment agreed that there is no need to complete this rulemaking since the agency issued an ANPRM (68 FR 39873) in 2003 to address this issue.
(Response) The agency agrees. Therefore, FDA is withdrawing this proposed rule.
11. Canned Pineapple; Proposal to Amend Standards of Identity and Quality—Docket No. 88P-0224, March 24, 1989, 54 FR 12237
FDA received two comments opposing the withdrawal of this proposed rule.
(Comment 9) One comment requested that, if FDA withdraws the proposed rule, FDA allow marketing for canned pineapple as a nonstandardized product.
(Response) FDA is denying this request because a product that purports to be or is represented as a food for which a standard of identity has been prescribed (e.g., canned pineapple) that does not comply with the provisions of that standard is misbranded under Start Printed Page 68834section 403(g) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 343(g)). FDA notes, however, that regulations in § 130.17 (21 CFR 130.17) provide that manufacturers may market foods that deviate from established standards of identity if they receive temporary marketing permits from FDA.
(Comment 10) The second comment stated that there are temporary marketing permits issued under this proposal that would not be valid if the proposal is withdrawn.
(Response) The comment is incorrect. There are no active temporary marketing permits to market test a “whole” style of canned pineapple that are the basis of this proposed rule. There were two temporary market permits that were issued in 1988 to Dole Packaged Foods Co. (53 FR 16471, May 9, 1988) and to Del Monte Corp. (53 FR 23602, June 22, 1988), which expired after 15 months. The agency is withdrawing this proposed rule.
12. Current Good Manufacturing Practices; Proposed Exemption From Active Ingredient Identity and Strength Testing for Homoeopathic Drug Products—Docket No. 79P-0265, April 1, 1983, 48 FR 14003
(Comment 11) The agency received one comment opposing the withdrawal of this proposed rule which would have exempted homeopathic drugs from the current good manufacturing practice (CGMP) requirements that drug products be tested for identity and strength of each active ingredient prior to release for distribution. The comment expressed concerns about possible changes in our enforcement policy towards final release testing of homeopathic drugs.
(Response) There may be instances where testing of a homeopathic product for identity and strength of the active ingredients prior to release for distribution would be appropriate and consistent with protection of the public health. For example, in instances where a product includes an active ingredient that at certain levels could be toxic or otherwise pose a public health concern, finished product testing may be appropriate because the testing could identify a significant manufacturing or labeling error. Since requiring this testing when necessary to protect the public health is consistent with FDA's mandate, we are withdrawing the proposed rule.
13. Pineapple Juice; Proposal to Amend U.S. Standards of Identity and Quality—Docket No. 86P-0338, May 21, 1987, 52 FR 19169
FDA received two comments opposing the withdrawal of this proposed rule.
(Comment 12) One comment requested that if FDA withdraws the proposed rule, FDA allow marketing for pineapple juice as a nonstandardized product.
(Response) FDA is denying this request because a product that purports to be or is represented as a food for which a standard of identity has been prescribed (e.g., pineapple juice) that does not comply with the provisions of that standard is misbranded under section 403(g) of the act. FDA notes, however, that regulations in § 130.17 provide that manufacturers may market foods that deviate from established standards of identity if they receive temporary marketing permits from FDA.
(Comment 13) The second comment stated that this proposed rule allowed the addition of pineapple juice from concentrate to pineapple juice to increase the brix level. Because the proposed rule addressed the use of pineapple juice from concentrate, the comment asks the agency either to complete this rulemaking or to publish a notice of policy that 21 CFR 102.33 (which applies to nonstandardized juices) would apply to pineapple juice.
(Response) The comment is incorrect in stating that the proposed rule allowed the addition of pineapple juice from concentrate to increase the brix level of pineapple juice in § 146.185 (21 CFR 146.185). The proposed rule only proposed to amend the standard of identity to allow this change. This amendment would not be effective until the rule was finalized. Thus, currently, the standard of identity for pineapple juice in § 146.185 does not permit the use of pineapple juice from concentrate to increase the brix level. A manufacturer who wishes to market pineapple juice with added pineapple juice from concentrate to increase the brix level may apply for a temporary marketing permit to do so. The agency is withdrawing this proposed rule.
14. Regulation of Medical Foods—Docket No. 96N-0364, November 29, 1996, 61 FR 60661
(Comment 14) The agency received one comment opposing the withdrawal of this ANPRM. The comment stated that manufacturers are marketing therapeutic products directly to consumers without prior FDA approval of health claims or FDA review of the suitability of the ingredients for the intended population. The comment stated that current FDA policies in this area create a loophole for manufacturers to make unauthorized health claims and use ingredients that may not be GRAS.
(Response) This comment does not persuade FDA that the ANPRM should not be withdrawn. Because of competing priorities that have tied up FDA's limited resources, the agency has been unable to consider, in a timely manner, the issues raised by comments on the ANPRM, and does not foresee having sufficient resources in the near term to do so. Therefore, the agency is withdrawing this ANPRM. However, FDA believes that the basic principles described in the ANPRM provide an appropriate framework for understanding the regulatory paradigm governing medical foods. Therefore, FDA advises that it will continue to refer to the basic principles described in the ANPRM and in FDA's Medical Foods Compliance Program (CP 7321.002) when evaluating medical foods. With regard to the specific points made in the comment regarding regulation of medical foods, the comment is correct that the act exempts medical foods from the nutrition labeling, health claim and nutrient content claim requirements that are applicable to most other foods. However, all statements on food labels (including medical foods) must be truthful and not misleading (see section 403(a)(1) of the act). FDA advises that medical foods with false or misleading labeling are subject to enforcement action. The agency also advises that withdrawal of this ANPRM does not change the requirement that all ingredients used in medical foods must be approved food additives, GRAS, or otherwise exempt from the food additive definition. Medical foods that do not comply with this requirement are subject to enforcement action.
15. Food Labeling: Nutrient Content Claims Pertaining to the Available Fat Content of Food—Docket Nos. 96N-0421 and 94P-0453/CP1, December 20, 1996, 61 FR 67243
(Comment 15) FDA received one comment opposing the withdrawal of this proposed rule. The comment states that misleading claims are being made by producers of products that contain nondigestible fat, including olestra, and that the total amount of fat in a product—regardless of whether it is digestible or nondigestible—should be declared to avoid consumer deception. The proposed rule responds in part to a citizen petition requesting use of digestibility coefficients in determining the quantity of fat declared in the label.
(Response) Currently, FDA regulations require that nutrition labeling and claims reflect the total amount of fat, which is defined as total lipid fatty acids and expressed as triglycerides § 101.9(c)(2) (21 CFR 101.9(c)(2)). The only exceptions to this general requirement are provided in the following: (1) The voluntary nutrition Start Printed Page 68835labeling final rule for raw fruit, vegetables, and fish (61 FR 42742, August 16, 1996) with respect to total fat in orange roughy fish and (2) the final rule for olestra (61 FR 3118, January 30, 1996) (61 FR 67243 at 67246). In the final rule for olestra, FDA specified that olestra need not be considered as a source of fat or calories for purposes of nutrition labeling or nutrient content claims (21 CFR 172.867(e)(5)).
By withdrawing this proposed rule, FDA will not be authorizing the use of digestibility coefficients, so that the total amount of fat in a product must be declared on the label whether it is digestible or nondigestible as provided in § 101.9(c)(2). However, withdrawing this proposed rule will have no effect on the nutrition labeling of products containing olestra or how the agency calculates the fat content of orange roughy for the purpose of voluntary nutrition labeling of that raw fish. Due to the agency's limited resources and other higher priority matters, the agency is withdrawing this proposed rule.
16. Food Labeling; Nutrient Content Claims and Health Claims; Special Requirements—Docket No. 95N-0103, February 2, 1996, 61 FR 3885
(Comment 16) The agency received one comment opposing the withdrawal of this proposed rule. The comment states that FDA access to records needed to evaluate the validity of nutrient content claims and health claims is essential to prevent consumer deception and ensure fair competition.
(Response) FDA continues to believe that, for health and nutrient content claims that pose particular enforcement difficulties, it would be valuable for the agency to have access to information that the manufacturer relied on in determining that the food meets the requirements of the claims. As the agency stated in the proposed rule (61 FR 3385 at 3889), the claims that are likely to present enforcement difficulties are those based on new food technology or a new use of food technology, those based on the results of novel or non-standardized testing procedures, and those which the agency cannot evaluate without information because the information is available only to the manufacturer. However, other higher priority matters require the agency's resources at this time, and therefore, the agency is withdrawing this proposed rule.
17. Food Labeling; Declaration of Free Glutamate in Food—Docket No. 96N-0244, September 12, 1996, 61 FR 48102
(Comment 17) FDA received two comments supporting the withdrawal of this ANPRM.
(Response) Thus, the agency is withdrawing this ANPRM.
For the reasons set forth previously, and under the act, the agency announces the withdrawal of the following documents, published in the Federal Register on the dates indicated in table 1:
|Title||Docket No.||FR Publication Date and Cite|
|Radioactive Drugs, Including Biological Products||75N-0069||July 25. 1975, 40 FR 31314|
|Conditions for Use of Methadone; Notice of Proposed Rulemaking||75N-0125||April 29, 1976, 41 FR 17922|
|Pasteurized Milk Ordinance and Interstate Milk Shippers||75N-0243||May 5, 1975, 40 FR 19513|
|Oral Contraceptive Drug Products; Physician and Patient Labeling||75N-0304||December 7, 1976, 41 FR 53633|
|Penicillin Streptomycin Powder; Penicillin-Dihydrostreptomycin Powder; Proposed Revocation of Certification Provision||75N-0374||July 9, 1976, 41 FR 28313|
|Conditions for Use of Methadone; Physiologic Dependence, Staffing, and Urine Testing Requirements||76N-0098||April 29, 1976, 41 FR 17926|
|Sorbic Acid and Its Salts; Proposed Affirmation and Deletion of GRAS Status||77G-03791||March 10, 1978, 43 FR 9823|
|Butylated Hydroxytoluene; Use Restrictions||77N-00031||May 31, 1977, 42 FR 27603|
|Color Additives; Proposed Use of Abbreviations for Labeling Foods, Drugs, Cosmetics, and Medical Devices||77N-0009 and 78P-0164||June 6, 1985, 50 FR 23815|
|Brown and Yellow Mustard and Their Derivatives; Proposed Affirmation of GRAS Status as Direct Human Food Ingredients||77N—00331||August 26, 1977, 42 FR 43092|
|Acrylonitrile Copolymers Intended for Use in Contact With Food; Proposed Rulemaking||77N—0078||March 11, 1977, 42 FR 13562|
|Gelatin; Affirmation of GRAS Status as a Direct and Indirect Human Food Ingredient||77N-02321||November 11, 1977, 42 FR 58763 and May 12, 1993, 58 FR 27959 (tentative final rule)|
|New Animal Drugs for Use in Animal Feeds; Animal Feeds Containing Penicillin and Tetracycline||77N-0318||January 20, 1978, 43 FR 3032|
|Ethylene Oxide, Ethylene Chlorohydrin, and Ethylene Glycol; Proposed Maximum Residue Limits and Maximum Levels of Exposure||77N-04241||June 23. 1978, 43 FR 27474|
|Label Designation of Ingredients in Cheese and Cheese Products||77P-0146||July 19, 1984, 49 FR 29242|
|Food Chemicals Codex Monographs; Opportunity for Public Comment on Revisions||78N-0072||April 18, 1978, 43 FR 16413|
|Start Printed Page 68836|
|Cellulose Derivatives; Affirmation of GRAS Status||78N-01441||February 23, 1979, 44 FR 10751|
|Tocopherols and Derivatives; Proposed Affirmation of GRAS Status for Certain Tocopherols and Removal of Certain Others From GRAS Status as Direct Human Food Ingredients||78N-02131||October 27, 1978, 43 FR 50193|
|Chlortetracycline-Sulfamethazine Tablets; Proposed Rulemaking||78N-0247||September 22, 1978, 43 FR 43036|
|Phosphates; Proposed Affirmation of and Deletion From GRAS Status as Direct and Human Food Ingredients||78N-0272||December 18, 1979, 44 FR 74845|
|Biotin; Proposed Affirmation of GRAS Status||78N-03081||January 14, 1983, 48 FR 1739|
|Lard and Lard Oil; Proposed Affirmation of GRAS Status as Indirect Human Food Ingredients||78N-03361||May 18, 1979, 44 FR 29102|
|Glycerin; Affirmation of GRAS Status as a Direct Human Food Ingredient||78N-03481||February 8, 1983, 48 FR 5758|
|Medical Devices; Classification of Sponges for Internal Use||78N-1074||November 28, 1978, 43 FR 55697|
|Medical Devices; Classification of Powered Myoelectric Biofeedback Equipment||78N-1183||August 28, 1979, 44 FR 50464|
|Porcine Burn Dressing||78N-2670||January 19 1982, 47 FR 2828|
|Food Ingredient Labeling; Emulsifiers and Stabilizers; Exemptions||78P-0052||April 17, 1985, 50 FR 15177|
|Sodium Dithionite and Zinc Dithionite; Proposed Affirmation of GRAS Status||79N-00951||January 25, 1980, 45 FR 6117 and September 17, 1982, 47 FR 41137 (tentative final rule)|
|Current Good Manufacturing Practice in Manufacture Processing, Packing, or Holding; Proposed Exemption From Active Ingredient Identity and Strength Testing for Homeopathic Drug Products||79P-0265||April 1, 1983, 48 FR 14003|
|Hydrochloric Acid; Proposed Affirmation of GRAS Status as a Direct Human Food Ingredient||80N-01481||April 26, 1984, 49 FR 17966|
|Cheeses and Related Cheese Products; General Standard of Identity for “Certain Other Cheeses”||80N-0373||April 23, 1984, 49 FR 17018|
|Caffeine; Deletion of GRAS Status, Proposed Declaration That No Prior Sanction Exists, and Use on an Interim Basis Pending Additional Study||80N-04181||October 21, 1980, 45 FR 69817|
|Policy for Recognizing Carcinogenic Chemicals in Food and Color Additives; Advance Notice of Proposed Rulemaking||81N-0281||April 2, 1982, 47 FR 14464|
|Magnesium Gluconate, Potassium Gluconate, Sodium Gluconate, Zinc Gluconate, and Gluconic Acid: Proposed GRAS Status as Direct and Indirect Human Food Ingredients||81N-0382||October 29, 1982, 47 FR 49028|
|Protein Hydrolysates and Enzymatically Hydrolyzed Animal (Milk Casein) Protein; Proposed GRAS Status||82N-00061||December 8, 1983, 48 FR 54990|
|Zinc Salts: Proposed Affirmation of GRAS Status||82N-01671||October 26, 1982, 47 FR 47441|
|Regenerated Collagen; Proposed GRAS Status as a Direct Human Food Ingredient||82N-02191||April 26,1983, 48 FR 18833|
|Ascorbic Acid and Its Sodium and Calcium Salts, Erythorbic Acid and Its Sodium Salt, and Ascorbyl Palmitate; Proposed Affirmation of GRAS Status and Removal of Calcium Ascorbate From the List of GRAS Ingredients||82N-02461||January 14, 1983, 48 FR 1735|
|Caffeine in Nonalcoholic Carbonated Beverages||82N-0318||May 20, 1987, 52 FR 18923|
|Common or Usual Names for Nonstandardized Foods; Diluted Fruit or Vegetable Juice Beverages||82N-0389||June 1, 1984, 49 FR 22831|
|Neurological Devices, Proposed Rule to Reclassify the Electroconvulsive Therapy Device Intended for Use in Treating Severe Depression||82P-0316||September 5, 1990, 55 FR 36578|
|New Drug and Antibiotic Application Review; Proposed User Charge||84N-0101||August 6, 1985, 50 FR 31726|
|Start Printed Page 68837|
|Proposed Uses of Vinyl Chloride Polymers||84N-0334||February 3, 1986, 51 FR 4177|
|Unmodified Food Starches and Acid Modifled Starches—Proposed Affirmation of GRAS Status as Direct and Indirect Human Food Ingredients||84N-03411||April 1, 1985, 50 FR 12821|
|Use of Acrylonitrile Copolymers||85N-0145||March 8, 1990, 55 FR 8476|
|Hematology and Pathology Devices; Premarket Approval of the Automated Blood Cell Separator Intended for Routine Collection of Blood and Blood Components||85N-0241||February 19, 1988, 53 FR 5108|
|New Drugs for Human Use: Proposed Clarification of Requirements for Application Supplements||86N-0077||June 4, 1986, 51 FR 20310|
|Quality Standards for Foods With No Identity Standards; Bottled Water||86N-0445||September 16, 1988, 53 FR 36063|
|Pineapple Juice; Proposal to Amend U.S. Standards of Identity and Quality||86P-0338||May 21, 1987, 52 FR 19169|
|New Animal Drug Regulations||88N-0058||December 17, 1991, 56 FR 65544|
|Current Good Manufacturing Practice for Blood and Blood Components; Proficiency Testing Requirements||88N-0413||June 6, 1989, 54 FR 24296|
|Canned Pineapple; Proposal To Amend Standards of Identity and Quality||88P-0224||March 24, 1989, 54 FR 12237|
|Shellac and Shellac Wax; Proposed Affirmation of GRAS Status With Specific Limitations as Direct Human Food Ingredients||89N-0106||July 26, 1989, 54 FR 31055|
|Erythromycin Capsules; Proposed Amendment of Dissolution Standard of Erythromycin Capsules||89N-03781||October 26, 1989, 54 FR 43592|
|Yogurt Products; Frozen Yogurt, Frozen Lowfat Yogurt, and Frozen Nonfat Yogurt; Petitions To Establish Standards of Identity and To Amend the Existing Standards||89P-0208 and 89P-0444||May 31, 1991, 56 FR 24760|
|Exemption From Preemption of State and Local Hearing Aid Requirements; Vermont||89P-0314||October 30, 1990, 55 FR 45615|
|Food Labeling; Declaration of Ingredients, Common or Usual Name Declaration for Protein Hydrolysates and Vegetable Broth in Canned Tuna; “and/or” Labeling for Soft Drinks||90N-0361M||January 6, 1993, 58 FR 2950|
|Use of Aseptic Processing and Terminal Sterilization in the Preparation of Sterile Pharmaceuticals for Human and Veterinary Use||91N-0074||October 11, 1991, 56 FR 51354|
|Cosmetic Products Containing Certain Hormone Ingredients; Notice of Proposed Rulemaking||91N-0245||September 9, 1993, 58 FR 47611|
|Substances in Food-Contact Articles in the Household, Food Service Establishments, and Food Dispensing Equipment; Food Additive Status||74-8424||April 12, 1974, 39 FR 13285|
|Drug Listing Compliance Verification Reports||92N-0291||September 2, 1993, 58 FR 46587|
|Food Labeling: Metric Labeling Requirements||92N-0406||May 21, 1993, 58 FR 29716|
|Food Labeling: Net Quantity of Contents; Compliance||92P-0441||March 4, 1997, 62 FR 9826|
|Cardiovascular Devices; Effective Date of Requirement for PMA of Nonroller-Type Cardiopulmonary Bypass Blood Pump||93M-0150||July 6, 1993, 58 FR 36290|
|Laser Products; Proposed Amendment to Performance Standards||93N-0044||March 24, 1999, 64 FR 14180|
|Quality Standards for Foods With No Identity Standards; Bottled Water||93N-0200||October 6, 1993, 58 FR 52042|
|Metric Labeling; Quantity of Contents Labeling Requirement for Foods, Human and Animal Drugs, Animal Foods, Cosmetics, and Medical Devices||92N-0406 and 93N-0226||December 21, 1993, 58 FR 67444|
|Lead in Food and Color Additives and GRAS Ingredients; Request for Data||93N-0348||February 4, 1994, 59 FR 5363|
|Substances Prohibited From Use in Animal Food or Feed; Specified Offal From Adult Sheep and Goats Prohibited in Ruminant Feed; Scrapie||93N-0467||August 29, 1994, 59 FR 44584|
|Start Printed Page 68838|
|Dental Devices; Effective Date of Requirement for Premarket Approval of Over-the-Counter (OTC) Denture Cushions or Pads and OTC Denture Repair Kits||95N-0034||July 11, 1995, 60 FR 35713|
|Food Labeling; Nutrient Content Claims and Health Claims; Special Requirements||95N-0103||February 2, 1996, 61 FR 3885|
|Maltodextrin; Food Chemicals Codex Specifications||95N-0189||September 21, 1995, 60 FR 48939|
|Beverages: Bottled Water||95N-0203||November 13, 1995, 60 FR 57132|
|Dental Devices; Effective Date of Requirement for Premarket Approval of Partially Fabricated Denture Kits||95N-0298||November 29, 1995, 60 FR 61232|
|Lowfat and Skim Milk Products, Lowfat and Nonfat Yogurt Products, Lowfat Cottage Cheese: Proposed Revocation of Standards of Identity; Food Labeling, Nutrient Content Claims for Fat, Fatty Acids and Cholesterol Content of Food||95P-0250||November 9, 1995, 60 FR 56541|
|Food Standards; Reinvention of Regulations Needing Revisions, Request for Comments on Certain Existing Regulations||96N-0149||June 12, 1996, 61 FR 29701|
|Reinvention of Certain Food Additive Regulations||96N-0177||June 12, 1996, 61 FR 29711|
|Food Labeling; Declaration of Free Glutamate In Food||96N-0244||September 12, 1996, 61 FR 48102|
|Regulation of Medical Foods||96N-0364||November 29, 1996, 61 FR 60661|
|Food Labeling: Nutrient Content Claims Pertaining to the Available Fat Content of Food||96N-0421 and 94P-0453/CP1||December 20, 1996, 61 FR 67243|
|Food Labeling; Serving Sizes; Reference Amounts for Candies||96P-0023 and 96P-0179||January 8, 1998, 63 FR 1078|
|1 Denotes documents that were included in the December 1991 withdrawal notice, but were not withdrawn at that time.|
Dated: August 30, 2004.
William K. Hubbard,
Associate Commissioner for Policy and Planning.
[FR Doc. 04-26234 Filed 11-24-04; 8:45 am]
BILLING CODE 4160-01-S